

PATENT Customer No. 22,852 Attorney Docket No. 03495-0178-01000

IN THE UNITED STATES PATE	NT AND TRADEMARK OFFICE
In re Application of:	<u>v</u>
LADANT et al.	Group Art Unit: 1645
Application No.: 09/973,013) Examiner: Zeman, Robert A.
Filed: October 10, 2001	Confirmation No.: 4881
For: BACTERIAL MULTI-HYBRID SYSTEM AND APPLICATIONS	COPY
Organization of Districts	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO NOTICE TO COMPLY

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed March 11, 2005, Applicants submit the attached Sequence Listing, in paper and computer readable form, Statement to Support Submission, Supplemental Preliminary Amendment directing its entry into the specification, and copy of the Notice to Comply. In addition, Applicants submit a Petition for Extension of Time for five months.

Please grant any further extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: September 9, 2005

By: Deborah Katz

Reg. No. 51,863 Phone: (202) 408-4382 Fax: (202) 408-4400

E-mail: deborah.katz@finnegan.com



FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER

901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413

PAPER NUMBER ART UNIT 1645

DATE MAILED: 03/11/2005

MIR 1 8 2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Robert A. Zeman

ART UNIT

PAPER

1645

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866.

lohet Zena

April cation No.: 09/973,013

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SECUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. 3 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant=s attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a ASequence Listing≅ as required by 37 C.F.R. 1.821(c).
	3. A copy of the ASequence Listing≅ in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the ASequence Listing≅ in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up ARaw Sequence Listing.≅
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the ASequence Listing≅ is not the same as the computer readable from of the ASequence Listing≅ as required by 37 C.F.R. 1.821(e).
X	7. Other: the sequence listing of record does not properly list the Application number and prior application numbers. See MPEP 2424.02.
Ар	plicant Must Provide:
	An initial or <u>substitute</u> computer readable form (CRF) copy of the ASequence Listing≅.
X	An initial or <u>substitute</u> paper copy of the ASequence Listing≅, as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support
	Technical Assistance

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY